<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[mike havrilla Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/mike+havrilla.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to mike havrilla]]></description>
	<s:counts start="0" returned="20" found="101" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Echo Therapeutics: Positive Developments for a Needle-Free Diabetes Monitoring System]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174299-echo-therapeutics-positive-developments-for-a-needle-free-diabetes-monitoring-system%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Echo Therapeutics (ECTE.OB) is a diabetes management company developing the needle-free Symphony Transdermal Continuous Glucose Monitoring tCGM System as a non-invasive, wireless, transdermal solution for monitoring blood sugar levels and the needle-free Prelude SkinPrep System for transdermal drug delivery applications.    On 11/19/09, the Company...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 19 Nov 2009 07:02:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[Access Pharma Looking for Smooth U.S. MuGard Launch in 2010]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172861-access-pharma-looking-for-smooth-u-s-mugard-launch-in-2010%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits:Access Pharma (ACCP.OB) provided an update Wednesday on the status of its FDA cleared treatment for oral mucositis, MuGard. The drug's North American commercial launch is expected to occur during 1Q10 in conjunction with the availability of initial product inventory by its liquid contract manufacturing partner, Accupac. In...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 11 Nov 2009 01:53:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[EXACT Sciences: Buy and Hold for Long-Term Upside]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172047-exact-sciences-buy-and-hold-for-long-term-upside%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: EXACT Sciences (NASDAQ: EXAS) is a molecular diagnostics company that is developing a next-generation (V3), stool DNA sDNA based screening test for colorectal cancer CRC which has demonstrated the ability to detect both early-stage cancer and pre-cancerous growths. The company's sDNA-based screening technology platform has also demonstrated...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 08 Nov 2009 03:16:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/exact+sciences+corp..html"><![CDATA[EXACT Sciences Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EXAS</category>
		<category domain="tickers">EXAS</category>
	</item>
	<item>
		<title><![CDATA[EXACT Sciences: Patience Required for Long-Term Upside]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F171106-exact-sciences-patience-required-for-long-term-upside%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company&#8217;s progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer CRC. EXAS reported total revenue of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 04 Nov 2009 04:16:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/exact+sciences+corp..html"><![CDATA[EXACT Sciences Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EXAS</category>
		<category domain="tickers">EXAS</category>
	</item>
	<item>
		<title><![CDATA[BioMed News Bytes: Dyax, Human Genome Sciences, Aldagen]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F169841-biomed-news-bytes-dyax-human-genome-sciences-aldagen%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits:The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 29 Oct 2009 08:02:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/dyax+corp..html"><![CDATA[Dyax Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/human+genome+sciences+inc..html"><![CDATA[Human Genome Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DYAX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HGSI</category>
		<category domain="tickers">DYAX,HGSI</category>
	</item>
	<item>
		<title><![CDATA[Celldex Therapeutics: Plenty of Cash, Pending Clinical Catalysts]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167492-celldex-therapeutics-plenty-of-cash-pending-clinical-catalysts%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: At the beginning of the month, Celldex Therapeutics CLDX announced the successful completion of its acquisition of CuraGen formerly CRGN, which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the pipeline and increasing the expected news flow of clinical data catalysts for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 20 Oct 2009 02:50:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[NF Energy: Continuing Its Robust Growth]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167204-nf-energy-continuing-its-robust-growth%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: NF Energy Saving Corp. (OTC: NFEC.OB) provides emission reduction and energy saving equipment / services for China&#8217;s rapidly growing cogeneration sector. The Company also manufactures wind power equipment and flow control systems for coal, hydro, and nuclear cogeneration facilities with an additional wind energy infrastructure manufacturing plant...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 19 Oct 2009 12:54:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/energy.html"><![CDATA[Energy]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[BioMed News Bytes: Cytori, Questcor]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166959-biomed-news-bytes-cytori-questcor%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits:Cytori Therapeutics CYTX sent out an email alert to investors on 10/15/09 in the evening pertaining to results that were presented at the 7th Annual Meeting of the International Federation for Adipose Therapeutics and Science IFATS that demonstrated the safety and feasibility of using a patient&#8217;s own adipose-derived...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 16 Oct 2009 05:09:31 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/cytori+therapeutics+inc..html"><![CDATA[Cytori Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTX</category>
		<category domain="tickers">CYTX</category>
	</item>
	<item>
		<title><![CDATA[BioMed News Bytes: Protalix, Soligenix]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166733-biomed-news-bytes-protalix-soligenix%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 10/15/09, Protalix BioTherapeutics (AMEX: PLX) announced positive top-line results of a pivotal Phase 3 study of its lead drug candidate, UPLYSO Taliglucerase Alfa in treatment naïve patients diagnosed with Gaucher disease.  In the study, UPLYSO met its primary endpoint of mean reduction in spleen volume...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 08:05:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html"><![CDATA[Protalix BioTherapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vulcan+energy+corp..html"><![CDATA[Vulcan Energy Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="tickers">PLX,PLX</category>
	</item>
	<item>
		<title><![CDATA[BioDelivery Sciences I sRestarting the Catalyst Cycle]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166730-biodelivery-sciences-i-srestarting-the-catalyst-cycle%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that develops new indications for approved drug compounds by applying its proprietary drug delivery technology platform, BEMA BioErodible MucoAdhesive Film Technology, while seeking FDA approval through the 505b(2) pathway, which represents a lower risk / cost and quicker...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 08:01:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/biodelivery+sciences+international+inc..html"><![CDATA[BioDelivery Sciences International Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BDSI</category>
		<category domain="tickers">BDSI</category>
	</item>
	<item>
		<title><![CDATA[Access Pharma: Clinical and Commercial MuGard Updates]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166690-access-pharma-clinical-and-commercial-mugard-updates%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Access Pharma (OTC: ACCP.OB) provided an update this morning on the clinical and commercial status of MuGard, which has already been launched by its partner, SpePharm, in five European countries for the prevention and treatment of oral mucositis. SpePharm is currently collecting information from approximately 1,500-2,000 patients...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 06:21:48 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[BioMed News Bytes: IntelGenx, Pressure BioSciences]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166667-biomed-news-bytes-intelgenx-pressure-biosciences%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 10/14/09, Pressure BioSciences (NASDAQ: PBIO) announced that they have entered into a strategic co-marketing / sales, R&D agreement with Protein Forest, Inc. The companies intend to co-market their product lines through industry publications, at scientific meetings, on their respective websites, through common collaborator studies, and at...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 04:51:44 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/pressure+biosciences+inc..html"><![CDATA[Pressure BioSciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PBIO</category>
		<category domain="tickers">PBIO</category>
	</item>
	<item>
		<title><![CDATA[Positive FDA Panel Outcome for Acorda Therapeutics]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166617-positive-fda-panel-outcome-for-acorda-therapeutics%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 4/23/09, Acorda Therapeutics ACOR announced the resubmission of its NDA for Fampridine-SR Amaya to the FDA as a new therapy being developed to improve walking ability in people with multiple sclerosis MS in response to a Refuse to File letter for the NDA issued by the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 01:14:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="tickers">ACOR</category>
	</item>
	<item>
		<title><![CDATA[Inovio Biomedical: DNA Vaccine Delivery Innovator]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F165695-inovio-biomedical-dna-vaccine-delivery-innovator%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms. Click here to visit...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 09 Oct 2009 03:32:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/inovio+biomedical+corp..html"><![CDATA[Inovio Biomedical Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">INO</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">INO,MRK</category>
	</item>
	<item>
		<title><![CDATA[NeoStem: A 3-Part China Merger Strategy]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F165469-neostem-a-3-part-china-merger-strategy%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: NeoStem (AMEX: NBS) is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of anti-aging / cosmetic medicine...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 08 Oct 2009 02:53:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/neostem+inc..html"><![CDATA[NeoStem Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NBS</category>
		<category domain="tickers">NBS</category>
	</item>
	<item>
		<title><![CDATA[Momenta Pharma's M-Enoxaparin: Timing Uncertain, Approval Likely]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F165226-momenta-pharma-s-m-enoxaparin-timing-uncertain-approval-likely%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Momenta Pharma (NASDAQ: MNTA) presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for the company, including an update on the FDA status for M-Enoxaparin.     In late September, the company raised net proceeds of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 07 Oct 2009 02:12:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/momenta+pharmaceuticals+inc..html"><![CDATA[Momenta Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MNTA</category>
		<category domain="tickers">MNTA</category>
	</item>
	<item>
		<title><![CDATA[Access Pharma and iMedicor Sign e-Marketing Deal for MuGard]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F165056-access-pharma-and-imedicor-sign-e-marketing-deal-for-mugard%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Access Pharma (ACCP.OB) announced an e-Marketing deal today with iMedicor (VMCI.OB) for the commercial launch of MuGard through the latter&#8217;s targeted marketing / education Alerts System application through NaviNet, which is a secure network of over 700,000 healthcare providers and support staff. Over 200,000 oncology-related clinicians in...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 06 Oct 2009 05:45:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[ImmunoCellular: Delivering on Key Milestones]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164085-immunocellular-delivering-on-key-milestones%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 9/30/09, ImmunoCellular Therapeutics (follow link for the Company&#8217;s Facebook page) (IMUC.OB) announced promising results from a pilot study evaluating the ability of the monoclonal antibody mAb, ICT-109, to distinguish between inflammatory conditions, cancerous, and non-cancerous tissue among pancreatic and lung cancer samples in the blood. ICT-109...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 30 Sep 2009 06:11:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
	</item>
	<item>
		<title><![CDATA[BioSante Pharma's LibiGel: Big Upside Potential]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F163604-biosante-pharma-s-libigel-big-upside-potential%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male testosterone deficiency hypogonadism. The company&#8217;s wholly-owned lead product is LibiGel transdermal testosterone gel, which is in Phase 3 clinical development by BioSante under dual Special...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 27 Sep 2009 03:08:21 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/biosante+pharmaceutical+inc..html"><![CDATA[Biosante Pharmaceutical Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BPAX</category>
		<category domain="tickers">BPAX</category>
	</item>
	<item>
		<title><![CDATA[Cytori Therapeutics' Cardiac Celution: Encouraging Interim Data]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162975-cytori-therapeutics-cardiac-celution-encouraging-interim-data%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells ADRCs to treat acute myocardial infarction (MI, heart attack) and chronic myocardial ischemia a severe form of coronary artery disease with...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 23 Sep 2009 06:27:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/cytori+therapeutics+inc..html"><![CDATA[Cytori Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTX</category>
		<category domain="tickers">CYTX</category>
	</item>
</channel>
</rss>
